Data and safety monitoring of rosiglitazone trials

Lancet

Volumn 369, Issue 9579, 2007, Pages 2077-

  Nabel, Elizabeth G ^a   Shurin, Susan B ^a   Simons Morton, Denise G ^a   Gordon, David ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE;

CLINICAL TRIAL; DRUG MONITORING; DRUG SAFETY; HUMAN; INSTITUTIONAL REVIEW; LETTER; MEDICAL PRACTICE; PRIORITY JOURNAL;

EID: 34250620911     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60975-1     Document Type: Letter

References (2)

1. Krall R. Cardiovascular safety of rosiglitazone. Lancet 369 (2007) 1995
2. Nissen S., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471